BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

BELLUS Health 

275 Armand-Frappier Boulevard

Laval  Quebec  H7V 4A7  Canada
Phone: 450-680-4500 Fax: 450-680-4501


SEARCH JOBS




Industry
Pharmaceutical






 Company News
Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) And BELLUS Health Announce Completion Of Enrollment In The Phase III Confirmatory Study of Kiacta™ For The Treatment Of AA Amyloidosis 5/28/2014 9:18:38 AM
Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) And BELLUS Health Announce Engagement Of Financial Advisor To Explore Sale Of KIACTA™, An Experimental Drug In Phase 3 Development For The Treatment Of AA Amyloidosis 5/7/2014 10:36:07 AM
Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) And BELLUS Health Announce Licence Agreement With Mount Sinai For KIACTATM In Sarcoidosis 5/2/2014 11:04:51 AM
BELLUS Health And AmorChem l.p. Announce A Partnership To Develop Drug Candidates For AL Amyloidosis 12/19/2013 1:24:55 PM
BELLUS Health Reports Results for Second Quarter Ended June 30, 2011 8/10/2011 10:41:32 AM
BELLUS Health Exercises Option to Terminate Lease 1/14/2011 12:10:37 PM
BELLUS Health and Celtic Therapeutics Enter Agreement Worth $20 Million for Drug candidate KIACTA(TM) 4/30/2010 1:08:14 PM
Geller Biopharm Successfully Advises BELLUS Health in Its KIACTA(TM) Transaction With Celtic Therapeutics 4/30/2010 10:38:16 AM
Roberto Bellini Appointed President and CEO of BELLUS Health 12/15/2009 6:44:10 AM
BELLUS Health Reports Results for First Half of Fiscal 2009 8/12/2009 8:49:25 AM
12